Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: Overall results from the GeparTrio study

Breast Cancer Research and Treatment

Volumn 124, Issue 1, 2010, Pages 133-140

  Huober, Jens ^a,b   Von Minckwitz, Gunter ^c   Denkert, Carsten ^d   Tesch, Hans ^e   Weiss, Erich ^f   Zahm, Dirk Michael ^g   Belau, Antje ^h   Khandan, Fariba ⁱ   Hauschild, Maik ^j   Thomssen, Christoph ^k   Högel, Bernhard ^l   Darb Esfahani, Silvia ^d   Mehta, Keyur ^c   Loibl, Sibylle ^c  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN BREAST GROUP   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Bethanien Krankenhaus Frankfurt   (Germany)

^f Hospital Sindelfingen Böblingen   (Germany)

^g SRH Waldkliniken ^*  (Germany)

^h UNIVERSITY OF GREIFSWALD   (Germany)

ⁱ AGAPLESION MARKUS KRANKENHAUS   (Germany)

^j Hospital of Rheinfelden   (Germany)

^k MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^l Frauenklinik Vom Roten Kreuz   (Germany)

more..

Author keywords

Age; Breast cancer; Lobular histology; Neoadjuvant chemotherapy; Predictive factors

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NAVELBINE; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PHENOTYPE; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FLUOROURACIL; GERMANY; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PHENOTYPE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 77957710541     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1103-9     Document Type: Article

References (22)

1. S Darb-Esfahani S Loibl BM Müller, et al. 2009 Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy Breast Cancer Res 11 R69 10.1186/bcr2363 19758440
2. G von Minckwitz HP Sinn G Raab, et al. 2008 Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast Breast Cancer Res 10 2 R30 10.1186/bcr1989
3. R Rouzier CM Perou WF Symmans, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 1:CAS:528:DC%2BD2MXos1Cjs7k%3D 10.1158/1078-0432.CCR-04-2421 16115903
4. M Colleoni G Viale D Zahrieh, et al. 2008 Expression of ER, PgR, HER1, HER2 and response: a study of preoperative chemotherapy Ann Oncol 19 465 472 1:STN:280:DC%2BD1c7ksVWlsA%3D%3D 10.1093/annonc/mdm509 17986623
5. M Colleoni V Bagnardi N Rotmensz, et al. 2009 Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy Breast Cancer Res Treat 116 359 369 1:CAS:528:DC%2BD1MXntF2ntrY%3D 10.1007/s10549-008-0223-y 18941889
6. G von Minckwitz G Raab A Caputo, et al. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the Geparduo study of the German Breast Group J Clin Oncol 23 2676 2685 10.1200/JCO.2005.05.078
7. G von Minckwitz S Kuemmel P Vogel, et al. 2008 Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study J Natl Cancer Inst 100 552 562 10.1093/jnci/djn089
8. G von Minckwitz S Kümmel P Vogel, et al. 2008 Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: a phase III randomized GeparTrio trial J Natl Cancer Inst 100 542 551 10.1093/jnci/djn085
9. HP Sinn H Schmid H Junkermann, et al. 1994 Histological regression of breast cancer after primary (neoadjuvant) chemotherapy Geburtsh u Frauenheilk 54 552 558 1:STN:280:DyaK2M%2FpsFSjuw%3D%3D 10.1055/s-2007-1022338
10. Loibl S, Müller B, Roller M et al. (2008) Local versus central HER2 immunohistochemistry correlates with kinetic RT-PCR but only central immunohistochemistry and RT-PCR predict pathological complete response: results from the neoadjuvant multicenter Gepar-Trio trial. Cancer Res 69(Suppl) (2): Abstract 1070
11. V Guarneri K Broglio S-W Kau, et al. 2006 Prognostic value of pathological complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 10.1200/JCO.2005.02.6914 16505422
12. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 1:CAS:528:DC%2BD3MXntVGmsbo%3D 10.1073/pnas.191367098 11553815
13. C Liedtke C Hatzis FW Symmans, et al. 2009 Genomic Grade Index is associated with response to chemotherapy in patients with breast cancer J Clin Oncol 27 3185 3191 10.1200/JCO.2008.18.5934 19364972
14. von Minckwitz G, Budczies J, Loibl S et al. (2009) Validated 3 gene signature predicts response to neo-adjuvant chemotherapy in luminal breast cancer-results from GeparTrio and GeparQuattro study. Cancer Res 69(Suppl) (24): Abstract 2132
15. C Mazoumi F Peintinger S Wan-Kau, et al. 2007 Residual carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome J Clin Oncol 25 2650 2655 10.1200/JCO.2006.08.2271
16. NS Goldstein D Decker D Severson, et al. 2007 Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy Cancer 110 1687 1696 1:CAS:528:DC%2BD2sXht1GksLzN 10.1002/cncr.22981 17722109
17. EA Rakha IO Ellis 2009 Triple-negative/basal-like breast cancer: review Pathology 41 40 47 10.1080/00313020802563510 19089739
18. C Liedtke C Mazouni KR Hess, et al. 2008 Response to neoadjuvant chemotherapy and long term-survival in patients with triple negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
19. M Cristofanilli A Gonzalez-Angulo N Sneige, et al. 2005 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 23 41 48 10.1200/JCO.2005.03.111 15625359
20. A Katz EA Saad P Porter, et al. 2007 Primary systemic chemotherapy of invasive lobular carcinoma of the breast Lancet Oncol 8 55 62 1:CAS:528:DC%2BD2sXhsFGlsw%3D%3D 10.1016/S1470-2045(06)71011-7 17196511
21. BC Pestalozzi D Zahrieh E Mallon, et al. 2008 Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials J Clin Oncol 18 3006 3014 10.1200/JCO.2007.14.9336
22. H Bonnefoi A Potti M Delorenzi, et al. 2007 Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial Lancet Oncol 8 1071 1078 1:CAS:528:DC%2BD2sXhsVWjur%2FK 10.1016/S1470-2045(07)70345-5 18024211